Fujirebio Europe launches Lumipulse® G B•R•A•H•M•S PCT for fully automated testing on the LUMIPULSE G series

“B•R•A•H•M•S PCT almost needs no further introduction; it is widely recognized as giving the best results when diagnosing bacterial infection and sepsis, leading to critical decision making in ER and ICU across the World.” said Christiaan De Wilde, CEO of Fujirebio Europe. “It was important to our customers that we make this high quality procalcitonin assay available on our LUMIPULSE G range. We are very proud to claim that Lumipulse G B•R•A•H•M•S PCT has turned out to be the most sensitive fully automated PCT test available on the market today!”

Procalcitonin (PCT) is a biomarker used for the diagnosis of bacterial infection and sepsis. The use of PCT has increased in clinical practice for improved patient management, in a variety of settings including primary care, emergency room (ER) and intensive care units (ICU). PCT has several advantages over other biomarkers for sepsis, such as C-Reactive Protein (CRP) and white blood cell count, as PCT is more specific. PCT helps in the differentiation of an infection and provides a correct clinical interpretation through an accurate test, and it also provides information about the host response to the infection.

Lumipulse G B•R•A•H•M•S PCT products (cartridges, calibrators and controls) are ordered at Fujirebio and are delivered directly from our warehouse.

The product mentioned in this press release might not be available in the USA and in Canada. Please contact us for further information.

About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 65 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and employes more than 1.300 people in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.